A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Etigilimab (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2018 According to an OncoMed Pharmaceuticals media release, data from this trial is expected in 2019.
    • 12 Jun 2018 According to an OncoMed Pharmaceuticals media release, the first patient has been dosed in the phase Ib portion of this trial. The company plans to enrol 12 patients in this phase Ib portion.
    • 08 May 2018 According to an OncoMed Pharmaceuticals media release, company plans to initiate dosing of the Phase 1b portion in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top